MSTR has just reported its August 5 earnings and the read across the data is a stock where the bull-case call positioning largely held, shorts have retreated further, but the analyst community is quietly walking down its price targets even as it keeps its ratings unchanged.
The options picture followed through on the call-heavy lean documented in Tuesday's preview. The put/call ratio has settled back to 0.948 — still nearly two standard deviations below the 20-day mean of 1.003, and well below the defensive 1.04 reading from the pre-July 30 note. That is a meaningful normalisation from the extreme sub-0.90 print flagged yesterday, but the direction of travel remains call-oriented. The 52-week range runs from 0.758 to 1.445, so at 0.948 the market is leaning toward upside exposure rather than hedging. The borrow market reinforces that read: availability has loosened further to 379% of short interest — up 25% on the week and back near the top of its recent range, far above the 52-week floor of 132%. Cost to borrow ticked marginally higher this week to 0.49%, but at that level it is effectively free to borrow. None of the lending signals point to squeeze risk.
Short interest has continued its quiet erosion. Bears now hold around 37.3 million shares, equal to roughly 13.9% of the free float — down 4.4% on the week and the lowest level since at least late June, when the short count peaked above 40.6 million. The drift lower has been gradual and consistent across every week tracked in this column. Positioning looks less combative than crowded: the shorts that remain are paying next to nothing to hold their view, and the lending pool is ample enough that new shorts face no friction.
The analyst angle tells a more complicated story. Targets have been cut broadly and repeatedly — B. Riley lowered to $155 from $215, Cantor Fitzgerald to $186 from $212, and Barclays to $125 from $130, all on August 3 alone. Benchmark's Mark Palmer cut sharply to $435 from $570 on July 31, though that target sits far above the current price and should be treated with caution given the gap to the $97.65 close. The consensus mean of $257.50 implies roughly 163% upside on paper, but the pattern of cuts — every firm moving in the same direction — matters more than the absolute levels. Crucially, not one firm has downgraded. BTIG reiterated Buy at $250. Barclays initiated at Overweight in early July and has already cut once. The analyst recommendation differential factor scores in the 94th percentile, reflecting a still-wide consensus premium to current price. The EV/EBITDA of 667x underscores that any traditional valuation framework struggles here — this remains predominantly a Bitcoin NAV proxy.
Capital Research and Management built the largest institutional position to the largest holder slot, holding 43.4 million shares (11.3% of the company) as of June 30, with a 12.8 million share addition in the quarter. BlackRock added 3.1 million shares to reach 4.6% over the same period. Both moves are notable in size. The insider picture is less clean: director Jarrod Patten has been a consistent seller across July, offloading small tranches at prices ranging from $92 to $100. The CEO and CFO also sold in June. The 90-day net insider figure is technically positive at 56,618 shares net, but that masks the recent directional tilt — every recent trade on record is a sale.
The July 30 earnings event produced a near-flat one-day move of -0.05%. An earlier print in June moved -2.8% on day one before recovering 8.9% over the following five days. That pattern — muted or mildly negative on the day, recovery into the following week — is the only read available from recent history. The August 5 print has now landed; the five-day reaction window is what to watch from here.
See the live data behind this article on ORTEX.
Open MSTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
